NCT02227901View on ClinicalTrials.gov

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

June 30, 2007

Study Completion Date

April 30, 2014

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma
Interventions
DRUG

Tipifarnib

Given PO

RADIATION

External Beam Radiation Therapy

Undergo EBRT

DRUG

Temozolomide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

90095

Ronald Reagan UCLA Medical Center, Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02227901 - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter